BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface

Background:The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is a risk prediction model that is used to compute probabilities of carrying mutations in the high-risk breast and ovarian cancer susceptibility genes BRCA1 and BRCA2, and to estimate the future risks of developing breast or ovarian cancer. In this paper, we describe updates to the BOADICEA model that extend its capabilities, make it easier to use in a clinical setting and yield more accurate predictions.Methods:We describe: (1) updates to the statistical model to include cancer incidences from multiple populations; (2) updates to the distributions of tumour pathology characteristics using new data on BRCA1 and BRCA2 mutation carriers and women with breast cancer from the general population; (3) improvements to the computational efficiency of the algorithm so that risk calculations now run substantially faster; and (4) updates to the model’s web interface to accommodate these new features and to make it easier to use in a clinical setting.Results:We present results derived using the updated model, and demonstrate that the changes have a significant impact on risk predictions.Conclusion:All updates have been implemented in a new version of the BOADICEA web interface that is now available for general use: http://ccge.medschl.cam.ac.uk/boadicea/.

[1]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[2]  Samuel H. Fuller,et al.  Computing Performance: Game Over or Next Level? , 2011, Computer.

[3]  G. Giles,et al.  Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre , 2013, British Journal of Cancer.

[4]  Jack J. Dongarra,et al.  Algorithm 679: A set of level 3 basic linear algebra subprograms: model implementation and test programs , 1990, TOMS.

[5]  M. Urioste,et al.  The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain , 2008, Clinical Cancer Research.

[6]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[7]  T. Rebbeck,et al.  Incorporating tumour pathology information into breast cancer risk prediction algorithms , 2010, Breast Cancer Research.

[8]  Patrick Neven,et al.  Genome-wide association studies identify four ER negative–specific breast cancer risk loci , 2013, Nature Genetics.

[9]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[10]  Päivi Heikkilä,et al.  Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[11]  E A Jones,et al.  Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing , 2009, Journal of Medical Genetics.

[12]  R. Elston,et al.  A general model for the genetic analysis of pedigree data. , 1971, Human heredity.

[13]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H O Dickinson,et al.  Cancer trends in England and Wales , 2000, BMJ : British Medical Journal.

[15]  Charles L. Lawson,et al.  Basic Linear Algebra Subprograms for Fortran Usage , 1979, TOMS.

[16]  R. Nussbaum,et al.  Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA ) , 2011 .

[17]  Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer , 2011, Familial Cancer.

[18]  C. Yip,et al.  Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer , 2008, Breast Cancer Research.

[19]  M. King,et al.  Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Schröck,et al.  Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium , 2013, Journal of Medical Genetics.

[21]  O. Brawley,et al.  Cancer screening in the United States, 2012 , 2012, CA: a cancer journal for clinicians.

[22]  H A Risch,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.

[23]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[24]  G. Parmigiani,et al.  Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction , 2008, Breast Cancer Research.

[25]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[26]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[27]  Douglas F. Easton,et al.  Clinical software development for the Web: lessons learned from the BOADICEA project , 2012, BMC Medical Informatics and Decision Making.

[28]  D. Easton,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.

[29]  Matthew J Hayat,et al.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. , 2007, The oncologist.

[30]  Jack J. Dongarra,et al.  A set of level 3 basic linear algebra subprograms , 1990, TOMS.

[31]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[32]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[33]  Patrick Neven,et al.  Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. , 2011, Human molecular genetics.

[34]  W. Cleveland.  Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .

[35]  L. Shulman.  Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2012 .

[36]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[37]  J. Chang-Claude,et al.  Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study , 2009, Cancer Epidemiology Biomarkers & Prevention.

[38]  K. Lange,et al.  Programs for pedigree analysis: Mendel, Fisher, and dGene , 1988, Genetic epidemiology.

[39]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[40]  R. Eeles,et al.  Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics , 2008, Journal of Medical Genetics.

[41]  N E Day,et al.  Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population‐based study , 2001, Genetic epidemiology.

[42]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[43]  Jacques Ferlay,et al.  NORDCAN – a Nordic tool for cancer information, planning, quality control and research , 2010, Acta oncologica.

[44]  Julie O. Culver,et al.  Essential Elements of Genetic Cancer Risk Assessment, Counseling, and Testing: Updated Recommendations of the National Society of Genetic Counselors , 2012, Journal of Genetic Counseling.